Delhi, India
Delhi, India

Time filter

Source Type

News Article | May 17, 2017
Site: www.prnewswire.com

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 164-page report you will receive 84 tables and 93 figures - all unavailable elsewhere. The 164-page report provides clear detailed insight into the global erythropoietin market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand new report today you stay better informed and ready to act. • Revenue forecasts of global erythropoietin market, segmented by product type: - Epoetin Alfa - Epoetin Beta - Darbepoetin Alfa - Biosimilars - Others This section also discusses the leading drugs as well as SWOT analysis of each submarket. • Revenue forecasts of global erythropoietin market, segmented by application: - Anemia (Cancer and HIV Treatment) - Kidney Disorders (ESRD and Dialysis) - Others Forecast for each regional market is further segmented by product type, application and country: - US - Canada - UK - Germany - France - Spain - Italy - Rest of Europe - China - Japan - India - Rest of Asia-Pacific - Brazil - Mexico - Rest of Latin America - Saudi Arabia - South Africa - Rest of Middle East and Africa • Assessment of selected leading companies that hold major market shares in the erythropoietin market: - Amgen - Johnson & Johnson - Roche - Biocon - 3SBio - Pfizer - Kyowa Hakko Kirin Co Ltd - LG Life Sciences Limited - Intas Pharmaceuticals Ltd - Novartis AG Visiongain's study is intended for anyone requiring commercial analyses for the erythropoietin market. You find data, trends and predictions. To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100 3SBio Inc. Accord Healthcare Limited Actavis Akebia Therapeutics Amgen Astellas Pharma Inc AstraZeneca Bio Sidus SA Biocon Ltd Casa Marzam Casa Saba Chugai Pharmaceutical Claes-Göran Östenson Corvidia Therapeutics DaVita Inc Dr. Reddy's Laboratories FibroGen First Shanghai Investments Limited Fresenius Medical Care North America (FMCNA) Galenica Germans Trias i Pujol Hospital GlaxoSmithKline H. Lundbeck A/S Hoffmann-La Roche Hospira Janssen Biotech Japan Chemical Research Pharmaceuticals Co., Ltd. Johnson & Johnson Kissei pharmaceuticals Kosin University Gospel Hospital Kyowa Hakko Kirin Co Ltd LG Life Sciences Limited NADRO NovaQuest Co-Investment Fund I, L.P. Novartis Institutes for BioMedical Research (NIBR) Novartis Pharmaceuticals NOXXON Pharma AG Pfizer Proveedora de Medicamentos RPG Life Sciences Sandoz Sirton Pharma Stada Stem Cell Therapeutics Corp. Teva Pharmaceutical Industries Ltd. UBI Pharma Inc. Vifor Pharma List of Organizations Mentioned in the Report Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) Centers of Disease Control and Preventions China's Ministry of Health (MOH) Committee for Medicinal Products for Human Use (CHMP) Department of Health & Family Welfare of Karnataka Deutsches Ärzteblatt EMA European Commission (EC) FDA Indian Council of Medical Research (ICMR) International Agency for Research on Cancer (IARC) Ministry of Health, Malaysia National Cancer Institute National Center for Biotechnology Information National Kidney Foundation UK Nephrology - Renal Association World Cancer Research Fund International World Health Organizations To see a report overview please email Sara Peerun on sara.peerun@visiongain.com


News Article | May 17, 2017
Site: www.prnewswire.co.uk

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 164-page report you will receive 84 tables and 93 figures - all unavailable elsewhere. The 164-page report provides clear detailed insight into the global erythropoietin market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand new report today you stay better informed and ready to act. • Revenue forecasts of global erythropoietin market, segmented by product type: - Epoetin Alfa - Epoetin Beta - Darbepoetin Alfa - Biosimilars - Others This section also discusses the leading drugs as well as SWOT analysis of each submarket. • Revenue forecasts of global erythropoietin market, segmented by application: - Anemia (Cancer and HIV Treatment) - Kidney Disorders (ESRD and Dialysis) - Others Forecast for each regional market is further segmented by product type, application and country: - US - Canada - UK - Germany - France - Spain - Italy - Rest of Europe - China - Japan - India - Rest of Asia-Pacific - Brazil - Mexico - Rest of Latin America - Saudi Arabia - South Africa - Rest of Middle East and Africa • Assessment of selected leading companies that hold major market shares in the erythropoietin market: - Amgen - Johnson & Johnson - Roche - Biocon - 3SBio - Pfizer - Kyowa Hakko Kirin Co Ltd - LG Life Sciences Limited - Intas Pharmaceuticals Ltd - Novartis AG Visiongain's study is intended for anyone requiring commercial analyses for the erythropoietin market. You find data, trends and predictions. To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100 3SBio Inc. Accord Healthcare Limited Actavis Akebia Therapeutics Amgen Astellas Pharma Inc AstraZeneca Bio Sidus SA Biocon Ltd Casa Marzam Casa Saba Chugai Pharmaceutical Claes-Göran Östenson Corvidia Therapeutics DaVita Inc Dr. Reddy's Laboratories FibroGen First Shanghai Investments Limited Fresenius Medical Care North America (FMCNA) Galenica Germans Trias i Pujol Hospital GlaxoSmithKline H. Lundbeck A/S Hoffmann-La Roche Hospira Janssen Biotech Japan Chemical Research Pharmaceuticals Co., Ltd. Johnson & Johnson Kissei pharmaceuticals Kosin University Gospel Hospital Kyowa Hakko Kirin Co Ltd LG Life Sciences Limited NADRO NovaQuest Co-Investment Fund I, L.P. Novartis Institutes for BioMedical Research (NIBR) Novartis Pharmaceuticals NOXXON Pharma AG Pfizer Proveedora de Medicamentos RPG Life Sciences Sandoz Sirton Pharma Stada Stem Cell Therapeutics Corp. Teva Pharmaceutical Industries Ltd. UBI Pharma Inc. Vifor Pharma List of Organizations Mentioned in the Report Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) Centers of Disease Control and Preventions China's Ministry of Health (MOH) Committee for Medicinal Products for Human Use (CHMP) Department of Health & Family Welfare of Karnataka Deutsches Ärzteblatt EMA European Commission (EC) FDA Indian Council of Medical Research (ICMR) International Agency for Research on Cancer (IARC) Ministry of Health, Malaysia National Cancer Institute National Center for Biotechnology Information National Kidney Foundation UK Nephrology - Renal Association World Cancer Research Fund International World Health Organizations To see a report overview please email Sara Peerun on sara.peerun@visiongain.com


News Article | April 17, 2017
Site: cen.acs.org

India is preparing to begin laboratory trials on a vector-control method to combat mosquito-borne viruses using a type of bacteria that infects insects. The work is part of a collaborative international effort to stem the spread of disease. An initial research phase will begin soon at Vector Control Research Centre in Puducherry, India, to study mosquitoes that are infected with Wolbachia bacteria. Though Wolbachia occurs in many insects, it is not usually found in the Aedes aegypti mosquito, a primary transmitter of the dengue and chikungunya viruses. Studies published last year show that Wolbachia can stop these viruses from growing inside the mosquitoes, and thus the bacteria might be used to control the spread of disease ( , DOI: 10.1371/journal.ppat.1005434; PLOS Neglected Trop. Dis., DOI: 10.1371/journal.pntd.0004677). In 2016, nearly 100,000 people across India tested positive for dengue, and more than 200 died of the disease, data from the National Vector Borne Disease Control Programme show. According to the agency, India had more than 58,000 suspected cases of chikungunya in 2016. Scientists at the research center, which functions under the Indian Council of Medical Research (ICMR), will work with A. aegypti larvae imported from Monash University that are infected with Wolbachia. ICMR entered into a partnership in February with Monash University’s Eliminate Dengue program. India was the sixth country to join the program, which is being implemented in Australia, Brazil, Colombia, Indonesia, and Vietnam.

Loading ICMR collaborators
Loading ICMR collaborators